Research Article

Calcium Channel Autoantibodies Predicted Sudden Cardiac Death and All-Cause Mortality in Patients with Ischemic and Nonischemic Chronic Heart Failure

Table 1

Clinical data of control subjects and patients with CHF.

Clinical characteristicControl (834)CHF
DCM ( ) ICM ( )

Male, (%)449 (53.84%)558 (76.23%)<0.001885 (80.53%)<0.001
Age (y) =0.052 <0.001
BMI =0.587 =0.453
NYHA class, (%)
 I834 (100%)00
 II0157 (21.45%)582 (52.96%)
 III0306 (41.80%)338 (30.76%)
 IV0269 (36.75%)179 (16.28%)
Hypertension, (%) 199 (23.86%)242 (33.06%)=0.003672 (61.15%)<0.001
Hyperlipidemia, (%) 53 (6.35%) 76 (10.38%)<0.001329 (29.94%)<0.001
Diabetes mellitus, (%)60 (7.19%) 120 (16.39%)<0.001317 (28.84%)<0.001
ECG and arrhythmias
 MHR (beats/min) <0.001 <0.001
 AF ( ) 0 177 (24.18%)130 (11.83%)
 PVC ( )0 192 (26.23%)217 (19.75%)
 QTc (ms) <0.001 <0.001
 QRS duration (ms) <0.001 <0.001
Hemodynamic parameters
 LVEF (%) <0.001 <0.001
 LVEDD (mm) <0.001 <0.001
Medications for CHF
 ACEI, (%) 0437 (59.69%)710 (64.60%)
 Diuretic, (%) 0565 (77.18%)741 (67.42%)
 Digoxin, (%) 0483 (65.98%)697 (63.42%)
-blocker, (%) 0570 (77.87%)776 (70.61%)
 CCBs, (%) 024 (3.28%)248 (22.57%)
ICD, (%)010 (1.37%)28 (2.55%)

Values are mean ± SD or number (%). was considered significant compared with the control group. Premature vascular contraction (PVC) indicated >3000 beats/24 h.
AF: atrial fibrillation; ACEI: angiotensin-converting enzyme inhibitor; BMI: body mass index; CHF: chronic heart failure; NYHA: New York Heart Association; DCM: dilated cardiomyopathy; ICM: ischaemic cardiomyopathy; LVEDD: left ventricular end-diastolic diameter; LVEF: left ventricular ejection fraction; MHR: mean heart rate; ICD: implantable cardioverter defibrillator; SCD: sudden cardiac death.